West Pharmaceutical Services (WST) EBITDA (2009 - 2026)

West Pharmaceutical Services (WST) has reported EBITDA for 18 consecutive years, with $179.1 million the latest figure, recorded in Q2 2026.

• Quarterly EBITDA rose 16.53% year-over-year to $179.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $680.4 million (up 16.99% YoY) and the FY2025 annual result came in at $584.9 million, up 2.63% from the prior year.
• EBITDA climbed to $179.1 million in Q2 2026 per WST's latest filing, from $177.1 million in the prior quarter.
• Over the last five years, EBITDA for WST reached as high as $228.4 million in Q2 2022 and fell as low as $107.0 million in Q1 2025.
• A 5-year average of $162.3 million and a median of $161.1 million in 2023 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA plunged 30.85% — and 2026, when it surged 65.51%.
• Year by year, EBITDA stood at $129.7 million in 2022, then gained by 24.06% to $160.9 million in 2023, then declined by 0.81% to $159.6 million in 2024, then fell by 1.88% to $156.6 million in 2025, then rose by 14.37% to $179.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $179.1 million, $177.1 million, and $156.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.